argenx SE reported $1000K in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AstraZeneca USD 340M 144M Jun/2026
Genmab DKK 139M 129M Jun/2026
GlaxoSmithKline GBP 121M 46M Jun/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Qiagen NV USD 10.02M 1.03M Jun/2026
UCB EUR 49M 29M Dec/2025